SCHEMBL7594332

SCHEMBL7594332

O=S(=O)(Nc1ccccc1NS(=O)(=O)c1cccs1)c1cccs1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.71
NPC1 O15118 1/20 0.71
GAA P10253 1/20 0.68
MEN1 O00255 4/20 0.64
KMT2A Q03164 4/20 0.64
TP53 P04637 2/20 0.64
BRAF P15056 1/20 0.64
HKDC1 Q2TB90 1/20 0.64
PKM P14618 2/20 0.63
MCOLN3 Q8TDD5 1/20 0.63
MAPT P10636 2/20 0.61
LMNA P02545 2/20 0.61
POLB P06746 1/20 0.61
MAPK1 P28482 1/20 0.61
NFKBIA P25963 1/20 0.60
RELA Q04206 1/20 0.60
GLO1 Q04760 1/20 0.60
KDM4E B2RXH2 1/20 0.60
HTT P42858 2/20 0.59
ALOX15 P16050 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7569883 0.88 PKM (0.79) ALDH1A1NPC1GAAMEN1KMT2A
SCHEMBL7578803 0.88 TP53 (0.73) ALDH1A1NPC1GAAMEN1KMT2A
SCHEMBL10878905 0.88 ALDH1A1 (0.61) ALDH1A1NPC1GAAMEN1KMT2A
SCHEMBL15009888 0.88 ALDH1A1 (0.61) ALDH1A1NPC1GAAMEN1KMT2A
SCHEMBL7578741 0.88 BRAF (0.68) ALDH1A1NPC1GAAMEN1KMT2A
SCHEMBL7573015 0.85 CCR2 (0.64) ALDH1A1NPC1MEN1KMT2ATP53
SCHEMBL463967 0.85 ALDH1A1 (0.58) ALDH1A1NPC1GAAMEN1KMT2A
SCHEMBL7570499 0.85 BRAF (0.65) ALDH1A1NPC1GAAMEN1KMT2A
SCHEMBL7571186 0.84 ALDH1A1 (1.00) ALDH1A1NPC1TP53LMNAPOLB
SCHEMBL4709087 0.82 MEN1 (0.84) ALDH1A1GAAMEN1KMT2ATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2955173-B1 1,2-BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS ALLERGAN INC (US) 2017-10-04 EP disclosed
US-9603834-B2 1,2- bis-sulfonamide derivatives as chemokine receptor modulators ALLERGAN, INC. (US) 2017-03-28 US disclosed
US-20160228407-A1 NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS ALLERGAN, INC. 2016-08-11 US disclosed
EP-2955173-A1 NOVEL 1,2-BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS ALLERGAN, INC. (US) 2015-12-16 EP disclosed
EP-2651901-B1 NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS ALLERGAN INC (US) 2015-05-27 EP disclosed
US-20140221351-A1 NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS ALLERGAN, INC. (US) 2014-08-07 US disclosed
US-8729066-B2 1,2- bis-sulfonamide derivatives as chemokine receptor modulators ALLERGAN, INC. (US) 2014-05-20 US disclosed
US-20140051682-A1 NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS ALLERGAN, INC. (US) 2014-02-20 US disclosed
US-8580779-B2 1,2-bis-sulfonamide derivatives as chemokine receptor modulators ALLERGAN, INC. (US) 2013-11-12 US disclosed
US-20120157444-A1 NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS ALLERGAN, INC. (US) 2012-06-21 US disclosed
EP-1239852-A2 BISSULFONAMIDE DERIVATIVES AS ENZYME INHIBITORS Arrow Therapeutics Limited (GB) 2002-09-18 EP disclosed
WO-2001028537-A2 BISSULFONAMIDE DERIVATIVES AS ENZYME INHIBITORS ARROW THERAPEUTICS LIMITED (GB) 2001-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160228407-A1 NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS CXCR2, CCR2, CX3CR1 ALDH1A1 2379/4885NPC1 2440/4885GAA 4465/4885
US-20140051682-A1 NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS CXCR2, CCR2, CX3CR1 ALDH1A1 2379/4885NPC1 2440/4885GAA 4465/4885
US-20140221351-A1 NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS CXCR2, CCR2, CX3CR1 ALDH1A1 2379/4885NPC1 2440/4885GAA 4465/4885
US-20120157444-A1 NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS CXCR2, CCR2, CX3CR1 ALDH1A1 2379/4885NPC1 2440/4885GAA 4465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.